Targeting autophagy enhances atezolizumab-induced mitochondria-related apoptosis in osteosarcoma

In this study, we identified the multifaceted effects of atezolizumab, a specific monoclonal antibody against PD-L1, in tumor suppression except for restoring antitumor immunity, and investigated the promising ways to improve its efficacy. Atezolizumab could inhibit the proliferation and induce immune-independent Apoptosis of osteosarcoma cells. With further exploration, we found that atezolizumab could impair mitochondria of osteosarcoma cells, resulting in increased release of Reactive Oxygen Species and cytochrome-c, eventually leading to mitochondrial-related Apoptosis via activating JNK pathway. Nevertheless, the excessive release of Reactive Oxygen Species also activated the protective Autophagy of osteosarcoma cells. Therefore, when we combined atezolizumab with Autophagy inhibitors, the cytotoxic effect of atezolizumab on osteosarcoma cells was significantly enhanced in vitro. Further in vivo experiments also confirmed that atezolizumab combined with chloroquine achieved the most significant antitumor effect. Taken together, our study indicates that atezolizumab can induce mitochondrial-related Apoptosis and protective Autophagy independently of the immune system, and targeting Autophagy is a promising combinatorial approach to amplify its cytotoxicity.